USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
PRECISION GENOME ENGINEERING, INC.
Address:
454 N 34TH ST
SEATTLE, WA 98103-8602
Phone:
N/A
URL:
N/A
EIN:
120511329
DUNS:
781229211
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $472,033.00 2
STTR Phase I $101,156.00 1
STTR Phase II $1,358,027.00 1

Award List:

Engineered nuclease for CCR5 gene editing

Award Year / Program / Phase:
2009 / STTR / Phase I
Award Amount:
$101,156.00
Agency:
HHS
Principal Investigator:
Research Institution:
SEATTLE CHILDREN'S HOSPITAL
RI Contact:
N/A
Abstract:
DESCRIPTION (provided by applicant): State the application's broad, long-term objectives and specific aims, making reference to the health relatedness of the project (i.e., relevance to the mission of the agency). Describe concisely the research design and methods for achieving these goals.… More

Engineered Nuclease for Glucocorticoid Receptor Gene Editing

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$174,053.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Genome engineering is an emerging field in which targeted genome modifications are made for biotechnological and therapeutic applications. Site specific rare cutting endonucleases are a crucial tool for genome engin eering, as they are required to create DNA… More

Modular custom nuclease platform for genome engineering therapies

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$297,980.00
Agency:
HHS
Principal Investigator:
Jordan Jarjour – 206-953-0712
Abstract:
DESCRIPTION (provided by applicant): Genome engineering is an emerging field in which genomic DNA sequences are modified for biotechnological and therapeutic purposes. Highly specific endonucleases are the key tool that enables genome engineering approaches, as they are required to create… More

Autologous HIV-1 resistant T cells through accelerated CCR5 gene disruption

Award Year / Program / Phase:
2013 / STTR / Phase II
Award Amount:
$1,358,027.00
Agency:
HHS
Principal Investigator:
Christian Burks – 206-225-7477
Research Institution:
SEATTLE CHILDRENS HOSPITAL
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): Treating patients infected with Human Immunodeficiency Virus-1 (HIV-1) is a substantial clinical challenge with evolving pharmaceutical drug and dosing options. Treatments should improve the health and quality of life for HIV-infected individuals by reducing… More